by Clinical Neuropsychologist Online | Wednesday, October 7, 2026 | Dementia
Abstract INTRODUCTION Anti-amyloid therapies can slow Alzheimer’s disease (AD) progression; diagnostic and treatment delays might reduce their value. METHODS Using dynamic microsimulation, we estimated the gross societal value of anti-amyloid treatment for...
by Clinical Neuropsychologist Online | Wednesday, October 7, 2026 | Dementia
Abstract INTRODUCTION Whether glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) activation lowers Alzheimer’s disease (AD) risk via peripheral metabolic improvement or direct neuroprotection remains unclear. METHODS Using blood and brain-cortex cis-acting...
by Clinical Neuropsychologist Online | Wednesday, October 7, 2026 | Dementia
Abstract INTRODUCTION Biological Alzheimer’s disease (AD) pathology does not fully explain the marked heterogeneity in clinical severity or progression. We investigated whether patient-derived induced microglia-like cell (iMG) profiles capture a functional...
by Clinical Neuropsychologist Online | Wednesday, October 7, 2026 | Dementia
Abstract INTRODUCTION Anti-amyloid antibody clinical trials with a high proportion of participants reaching treatment-related amyloid clearance (TRAC) had positive clinical outcomes. We evaluated the aducanumab phase 3 program to determine whether TRAC during the...
by Clinical Neuropsychologist Online | Wednesday, October 7, 2026 | Neurorehabilitation
. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: | October 7, 2026 Neuro-Rehab Previous Page
